Oncolytics After 2017 Refresh: New CEO Makes New Year Resolutions

2018 will be a year of change for Calgary, Canada-based Oncolytics Biotech, according to its CEO Dr. Matt Coffey. After switching gears to focus on metastatic breast cancer as the lead indication for its oncolytic virus-based drug candidate Reolysin, the biotech is ready to enter Phase III and step-up its clinical and commercial activities.

2018
Oncolytics prepares to launch Phase III trial in 2018 for lead drug • Source: Shutterstock

Oncolytics Biotech Inc., a Canadian firm developing an intravenous immuno-oncolytic virus agent against various cancers, is on a transformational path it hopes will lead the 1998-founded business towards a future as a leading immuno-oncology biotech.

In 2017, Oncolytics appointed new leadership members to its executive team and switched up its R&D focus from non-small cell...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.